Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents

Table 3

Clinical outcomes in both study arms.

	Magmaris group			Ultimaster group
Clinical outcomes	DM; ()	Non-DM; ()	value	DM; ()	Non-DM; ()	value
30-day follow-up
Primary outcome: cardiac death, myocardial infarction, and stent thrombosis	0 (0%)	0 (0%)	—	2 (3.4%)	0 (0%)
Principal secondary outcome: target lesion failure (cardiac death, target vessel myocardial infract, and target lesion revascularization)	0 (0%)	0 (0%)	—	0 (0%)	0 (0%)	—
Death
(i) Cardiac	0 (0%)	0 (0%)	—	0 (0%)	0 (0%)	—
(ii) Any	0 (0%)	0 (0%)	—	0 (0%)	0 (0%)	—
Myocardial infarction:
(i) Target vessel	0 (0%)	0 (0%)	—	0 (0%)	0 (0%)	—
(ii) Any	0 (0%)	0 (0%)	—	2 (3.4%)	0 (0%)
Scaffold:
(i) Thrombosis	0 (0%)	0 (0%)	—	0 (0%)	0 (0%)	—
(ii) Restenosis	0 (0%)	0 (0%)	—	0	0	—
Revascularization:
(i) Target lesion	0 (0%)	0 (0%)	—	0 (0%)	0 (0%)	—
(ii) Target vessel	0 (0%)	0 (0%)	—	0 (0%)	0 (0%)	—
(iii) Any	0 (0%)	0 (0%)	—	5 (8.5%)	4 (3.6%)
1-year follow-up
Primary outcome: cardiac death, myocardial infarction, and stent thrombosis	2 (2.7%)	1 (0.8%)		3 (5.1%)	6 (5.45%)
Principal secondary outcome: target lesion failure (cardiac death, target vessel myocardial infract, and target lesion revascularization)	3 (4.1%)	0 (0%)		2 (3.3%)	4 (3.6%)
Death
(i) Cardiac	0(0%)	0 (0%)	—	0 (0%)	0 (0%)	—
(ii) Any	2 (2.7%)	1 (2.33%)		0 (0%)	0 (0%)	—
Myocardial infarction:
(i) Target vessel	2 (2.7%)	0		1 (1.6%)	4 (3.6%)
(ii) Any	2 (2.7%)	1 (2.33%)		2 (3.4%)	2 (1.8%)
Scaffold:
(i) Thrombosis	0 (0%)	0	—	0 (0%)	0 (0%)	—
(ii) restenosis	2 (2.7%)	0		1 (1.7%)	1 (0.9%)
Revascularization:
(i) Target lesion	2 (2.7%)	0 (0%)		1 (1.7%)	2 (1.8%)
(ii) Target vessel	3 (2.7%)	0 (0%)		2 (3.4%)	5 (4.5%)
(iii) Any	10 (13.8%)	8 (6.6%)		10 (16.9%)	14 (12.7%)